Home » meropenem » Page 4

Tag Archives: meropenem

What’s in a Name?  Would ‘Carbavance’ Still Smell as Sweet?

Posted on by — No Comments ↓

Since the publication of a series of posters at ICAAC 2014, we finally know what’s hidden behind the ‘Carbavance’ name.  ‘Carbavance’ stands for the combination of meropenem with the B-lactamase inhibitor RPX7009 which The Medicines Company (TMC) inlicensed from Rempex Pharmaceuticals a few years ago.  This is the ‘Carbavance’ which Continue reading What’s in a Name?  Would ‘Carbavance’ Still Smell as Sweet?→

Perusing the Literature

Posted on by — No Comments ↓

Inhibitor of the NDM Enzyme Aspergillomarasmine (AMA) was identified as an inhibitor of the New Delhi metallo-betalactamase (NDM) enzyme. This substance, when combined with meropenem, restored antibiotic activity against an NDM lab strain.   AMA is a substance which was already tested in the past in humans.  Concerns about interference with human metalloenzymes proved Continue reading Perusing the Literature→

What is the “Niche” for Ceftolozane / Tazobactam?

Posted on by — 2 Comments ↓

There are currently a total of 6 beta-lactam + beta-lactamase inhibitor combinations in clinical trials. It will be a steep learning curve for the pharma reps (and physicians) to understand the resistance classifications, the confusing ESBL definitions, the CRE nomenclature, and how this all matters in clinical practice, on the Continue reading What is the “Niche” for Ceftolozane / Tazobactam?→